EVALUATING THE SAFETY OF DONEPEZIL HYDROCHLORIDE (ARICEPT) FOR UP TO 1 YEAR IN THE TREATMENT OF THE COGNITIVE DYSFUNCTION EXHIBITED BY CHILDREN WITH DOWN SYNDROME - FOLLOW-UP TO A 10-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL: